Trending...
- TradingHabits.com Launches to Support Day Trader Well-being
- Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
- Schemawriter.ai launches WordPress plugin as industry leaders confirm - schema markup is critical
IndyGeneUS plans to use the grant funding from Johnson & Johnson Innovation to Scale Blockchain-secured Genomic Data Marketplace and Proprietary GenēUS™ Discovery Platform
WASHINGTON - ncarol.com -- Today, IndyGeneUS AI was named an awardee of the Johnson & Johnson Innovation Veterans Lead QuickFire Challenge: Innovations by Vets.
Johnson & Johnson Innovation, together with Bunker Labs, a national nonprofit organization that aims to equip the military-connected community with the network, tools, and opportunities needed to launch and grow successful businesses, invited U.S. Veteran innovators and military spouses/legal partners to submit potentially ground-breaking ideas in all aspects of human healthcare.
The black-owned and Service-Disabled Veteran-owned Small Business (SDVOSB), IndyGeneUS AI, pitched their cutting-edge blockchain-encrypted and machine learning-powered bioinformatics "GenēUS™ Discovery Platform" to a panel of judges, which included both Johnson & Johnson Innovation and Bunker Labs executives.
"It's extremely important that we support the visions of our veterans," says Lenore Karafa, Board Member President of Bunker Labs. "I was excited to learn about the mission of IndyGeneUS AI, during their pitch and the hard work and dedication they are pouring into eradicating health disparities."
More on ncarol.com
IndyGeneUS AI is a precision genomics company aiming to create the world's largest blockchain-encrypted digital health platform of indigenous and diasporic African clinical and genomic data. Using proprietary technology, IndyGeneUS AI can potentially detect novel signature sequences, identify biomarkers, and calculate polygenic risk scores by integrating multi-omics data, electronic health record (EHR) data, and other textual information such as scientific manuscripts.
"This is literally a dream come true, and a bit nostalgic," said IndyGeneUS AI Founder, Yusuf Henriques. "Today, IndyGeneUS AI has its first lab set up at JLABS @ Washington, DC at Children's National new Research and Innovation Campus, on the former Walter Reed Army Medical Center campus. A site where I walked the halls as a combat medic in the U.S. Army, over 20-years ago. Now, I have an opportunity to identify novel cell & gene therapies that will hopefully address health disparities and rare diseases like retinitis pigmentosa (RP), which my twin daughters were diagnosed with in 2014. This is my opportunity to deliver on the promise that I made my girls to find better treatment options or a cure."
To aid in this mission, IndyGeneUS AI will provide workforce economic development to engage minority young men and women who desire to learn more about genomics and driving precision care through careers in biotech.
More on ncarol.com
In addition to being awarded the QuickFire Challenge, IndyGeneUS AI officially became a resident at JLABS @ Washington, DC on May 1st. IndyGeneUS AI has a strong commitment to driving precision health equity. Ninety percent of IndyGenUS' executive leadership and advisors are Howard University Alumni. The company will focus on whole genome sequencing which utilizes multiple next-generation DNA sequencing platforms and methodologies to identify genetic drivers of conditions disproportionately impacting Black, Brown, and Indigenous populations.
"We are leveraging genetic diversity via large-scale whole-genome sequencing to advance the understanding of the causes of human biology, health, and disease," said Dr. Bradford Wilson, IndyGeneUS AI -Chief Scientific Officer. "This will lay the foundation for precision therapeutics to reduce or eliminate health disparities globally."
For more information about IndyGeneUS AI visit: https://indygeneus.ai. For media inquiries contact: Angel Livas at angel@indygeneus.ai.
Johnson & Johnson Innovation, together with Bunker Labs, a national nonprofit organization that aims to equip the military-connected community with the network, tools, and opportunities needed to launch and grow successful businesses, invited U.S. Veteran innovators and military spouses/legal partners to submit potentially ground-breaking ideas in all aspects of human healthcare.
The black-owned and Service-Disabled Veteran-owned Small Business (SDVOSB), IndyGeneUS AI, pitched their cutting-edge blockchain-encrypted and machine learning-powered bioinformatics "GenēUS™ Discovery Platform" to a panel of judges, which included both Johnson & Johnson Innovation and Bunker Labs executives.
"It's extremely important that we support the visions of our veterans," says Lenore Karafa, Board Member President of Bunker Labs. "I was excited to learn about the mission of IndyGeneUS AI, during their pitch and the hard work and dedication they are pouring into eradicating health disparities."
More on ncarol.com
- Bent Danholm Releases New Video Breaking Down the Rising Debate Over 50-Year Mortgages
- New Smile Now Introduces RAYFace 3D Scanner to Advance Digital Surgery
- Ali Alijanian, DDS Featured in The Profitable Dentist Magazine
- My Utmost for His Highest — Oswald Chambers
- "Meet the Eatmons" Offer Financial Advice ahead of the Holidays
IndyGeneUS AI is a precision genomics company aiming to create the world's largest blockchain-encrypted digital health platform of indigenous and diasporic African clinical and genomic data. Using proprietary technology, IndyGeneUS AI can potentially detect novel signature sequences, identify biomarkers, and calculate polygenic risk scores by integrating multi-omics data, electronic health record (EHR) data, and other textual information such as scientific manuscripts.
"This is literally a dream come true, and a bit nostalgic," said IndyGeneUS AI Founder, Yusuf Henriques. "Today, IndyGeneUS AI has its first lab set up at JLABS @ Washington, DC at Children's National new Research and Innovation Campus, on the former Walter Reed Army Medical Center campus. A site where I walked the halls as a combat medic in the U.S. Army, over 20-years ago. Now, I have an opportunity to identify novel cell & gene therapies that will hopefully address health disparities and rare diseases like retinitis pigmentosa (RP), which my twin daughters were diagnosed with in 2014. This is my opportunity to deliver on the promise that I made my girls to find better treatment options or a cure."
To aid in this mission, IndyGeneUS AI will provide workforce economic development to engage minority young men and women who desire to learn more about genomics and driving precision care through careers in biotech.
More on ncarol.com
- CCHR: Study Finds Involuntary Commitment Fails to Prevent Suicide, Raises Risk
- Slotozilla's Q3 2025: SBC Lisbon Outcomes and Partnership Expansion
- Historic Announcement for the Global Car Rental Industry
- Siembra Brings 18 Latinx Artists Together in Brooklyn Exhibition
- Gramercy Tech Launches StoryStream
In addition to being awarded the QuickFire Challenge, IndyGeneUS AI officially became a resident at JLABS @ Washington, DC on May 1st. IndyGeneUS AI has a strong commitment to driving precision health equity. Ninety percent of IndyGenUS' executive leadership and advisors are Howard University Alumni. The company will focus on whole genome sequencing which utilizes multiple next-generation DNA sequencing platforms and methodologies to identify genetic drivers of conditions disproportionately impacting Black, Brown, and Indigenous populations.
"We are leveraging genetic diversity via large-scale whole-genome sequencing to advance the understanding of the causes of human biology, health, and disease," said Dr. Bradford Wilson, IndyGeneUS AI -Chief Scientific Officer. "This will lay the foundation for precision therapeutics to reduce or eliminate health disparities globally."
For more information about IndyGeneUS AI visit: https://indygeneus.ai. For media inquiries contact: Angel Livas at angel@indygeneus.ai.
Source: IndyGeneUS AI
Filed Under: Health
0 Comments
Latest on ncarol.com
- The Lashe® Announces Exclusive November Savings for Lash and Beauty Professionals
- Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
- November is Lung Cancer Awareness Month: Screening Saves Aims to Increase Access to Lung Screenings in NC
- Valeo Health Leads a New Era of Longevity and Preventive Health in the UAE
- Torch Entertainment Presents The Frozen Zoo
- Sweet Memories Vintage Tees Debuts Historic ORCA™ Beverage Nostalgic Soda Collection
- UK Financial Ltd Celebrates Global Recognition as MayaCat (MCAT) Evolves Into SMCAT — The World's First Meme Coin Under ERC-3643 Compliance
- Gold Is Money 2 Announces List of Top 5 Gold IRA Companies
- U.S. Military to Benefit from Drone Tech Agreement with NovaSpark Energy, Plus Longer NASA Space Missions via Solar Power Leader: Ascent Solar $ASTI
- Wise Business Plans Launches Tailored Business Plan Writing Services for North Carolina Entrepreneur
- $76 Million in Gold & Silver Holdings and Expanding Production — Pioneering the Future of Gold: Asia Broadband Inc. (Stock Symbol: AABB) is Surging
- Wohler announces three SRT monitoring enhancements for its iVAM2-MPEG monitor and the addition of front panel PID selection of A/V/subtitle streams
- Schemawriter.ai launches WordPress plugin as industry leaders confirm - schema markup is critical
- 20 Million Financing to Accelerate Growth and Advance Digital Asset Strategy Secured for Super League (N A S D A Q: SLE)
- uCAR Trading Launches goldsilbermarkt.de, a New Online Shop for Precious Metals
- Webinar Announcement: Reputational Risk Management in Internal Investigations: Controlling the Narrative Before, During, and After a Crisis
- Taking on the Multi-Billion-Dollar Swipe Industry: AI Curates Who You Meet—IRL over brunch
- BillyGoat Mulching Introduces Advanced Subsoil Mulching for Premium Land Finishing and Development
- Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
- Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion

